From the Infectious Diseases Unit, 3 Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece.
Institute of Pediatric Oncology (GRAACC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Pediatr Infect Dis J. 2020 Apr;39(4):305-309. doi: 10.1097/INF.0000000000002568.
Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.
19 名年龄在 1 个月至<2 岁的患者（n = 16）或有侵袭性念珠菌病高风险的患者（n = 3）接受了安尼达fungin 治疗 5-35 天（第 1 天 3mg/kg，此后每天 1.5mg/kg），随后可选氟康唑（NCT00761267）。大多数治疗期间出现的不良事件为轻度/中度，无治疗相关死亡。静脉治疗结束时的全球反应成功率为 68.8%。药代动力学与成年患者相似。
